Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Pain and Therapy|November 9, 2024
Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label StudyDavid Kudrow, Susan Hutchinson, Glenn C Pixton, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|September 14, 2013
A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraineEmily Rubenstein Engel, David Kudrow, Alan M Rapoport
Headache|June 30, 2025
A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraineDavid Kudrow, Robert S Croop, Alexandra Thiry, et al.
Cephalalgia : an International Journal of Headache|March 25, 2022
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migrainePeter McAllister, David Kudrow, Roger Cady, et al.
Headache|June 26, 2024
Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headacheAndrew Blumenfeld, David Kudrow, Peter McAllister, et al.
Neurology|January 15, 2020
Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapyKathleen Mullin, David Kudrow, Robert Croop, et al.
Headache|September 24, 2005
Valdecoxib for treatment of a single, acute, moderate to severe migraine headacheDavid Kudrow, H Mikel Thomas, Gary Ruoff, et al.
Clinical and Translational Science|January 19, 2021
Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factorJohn A Kessler, Aziz Shaibani, Christine N Sang, et al.
BMC Neurology|March 20, 2021
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trialDavid Kudrow, Roger K Cady, Brent Allan, et al.
BMC Neurology|November 11, 2018
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraineAngelo Camporeale, David Kudrow, Ryan Sides, et al.
Pageof 4